AB Science S.A. (EPA:AB)

Market Cap	89.00M +1.8%
Revenue (ttm)	1.03M -5.1%
Net Income	-8.54M
EPS	-0.15
Shares Out	72.95M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,480
Average Volume	107,009
Open	1.246
Previous Close	1.246
Day's Range	1.220 - 1.252
52-Week Range	0.970 - 1.730
Beta	1.36
RSI	36.64
Earnings Date	May 7, 2026

About AB Science

AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company’s lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyotrophic lateral sclerosis, progressive forms of multiple sclerosis, Alzheimer’s disease, and indolent systemic mastocytosis, as well as in Phase 2 tria...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 36
• Stock Exchange: Euronext Paris
• Ticker Symbol: AB

Financial Performance

In 2024, AB Science's revenue was 1.07 million, an increase of 10.52% compared to the previous year's 970,000. Losses were -7.83 million, -34.66% less than in 2023.